Product category:
Proteomics
News Release from: Nextgen Sciences
Edited by the Laboratorytalk Editorial
Team on 25 January 2006
NextGen lists on the London Stock
Exchange
NextGen says it has successfully completed its fundraising and admission to the AIM market of the London Stock Exchange and that trading of ordinary shares and warrants in the company has commenced
Nextgen Sciences is a provider of expert systems, services and reagents focussed on enabling enhanced access to, and understanding of the role of, proteins in diagnosis and drug discovery The expert systems are built out of NextGen Sciences's understanding of biological sciences and combine robotics, advanced engineering, and rules-based software in systems that range from partial to fully automated
This article was originally published on Laboratorytalk on 8 Dec 2003 at 8.00am (UK)
Related stories
Technologies to revolutionise protein research
Two new technologies that could make a significant impact on the pharmaceutical industry by improving protein analysis and accelerating drug discovery
Patent covers electrophoretic separation
Patent protects the system's ability to perform iso-electric focusing with the separation medium on one face of a flexible plastic sheet rather than the traditional and cumbersome glass plates
NextGen Sciences also uses its systems and instruments to provide fee-for-service products to the pharmaceutical and biotechnology industry as well as to those in academic research.
NextGen Sciences has developed a range of products several of which have already been marketed to the biopharmaceutical industry including OrchestratorIMS - an expert system which provides a link between biology, software and hardware; the ExpressionFactory, the ExpressionWorkstation, and the BaculoWorkstation - advanced robotics systems for high-throughput gene cloning and protein expression; the a2DE Optimizer - a proprietary instrument enabling the customisation of 2D electrophoresis gels, a major advance in protein analysis.
In addition, NextGen Sciences has introduced a growing range of consumable reagents for use with the above products.
As part of the listing the company undertook a placing of ordinary shares and warrants to raise net proceeds of approximately £1.9 million.
Commenting on the listing, James Heffernan, CEO of the company, said: "We are delighted that the company has been able to successfully list on AIM.
"The money we have raised should give the group the additional resource that it requires to commercialise its range of products and new drug discovery support services for the pharmaceutical and biotechnology industries.".
• Nextgen Sciences: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
